Kaiser Peter K
Cleveland Clinic, Cole Eye Institute, Cleveland, Ohio 44195, USA.
Retina. 2009 Jun;29(6 Suppl):S34-5. doi: 10.1097/IAE.0b013e3181ad242f.
Radiotherapy is a promising adjunctive tool to antiangiogenesis therapies for control of the choroidal neovascularization that characterizes exudative (wet) age-related macular degeneration. Historically, radiation monotherapy sufficient to effectively eradicate choroidal neovascularization has been associated with mixed results; however, newer techniques and delivery platforms have been developed to improve efficacy. The most significant improvements are technical advances that improve the precision of energy delivery, so that tissue destruction remains confined to the target. In addition, several combination therapies are showing promise for enhanced effect. Other strategies, such as pretreating neovascular tissue to increase its sensitivity to radiation, thereby reducing the energy dose, may also be viable. However, even though the modern delivery systems permit relatively low dosages, there are risks of radiotherapy to ocular tissue, and its role remains speculative, pending results of ongoing trials.
放射疗法是一种很有前景的辅助工具，可用于抗血管生成疗法，以控制渗出性（湿性）年龄相关性黄斑变性所特有的脉络膜新生血管形成。从历史上看，足以有效根除脉络膜新生血管的放射单一疗法效果不一；然而，已开发出更新的技术和给药平台来提高疗效。最显著的改进是技术进步，提高了能量传递的精度，从而使组织破坏局限于目标部位。此外，几种联合疗法显示出增强疗效的前景。其他策略，如预处理新生血管组织以增加其对辐射的敏感性，从而降低能量剂量，也可能是可行的。然而，尽管现代给药系统允许相对较低的剂量，但放射疗法对眼组织仍有风险，在正在进行的试验结果出来之前，其作用仍具有推测性。
